酪氨酸激酶抑制剂引起的肝损伤机制研究进展  

Research progress on mechanism of tyrosine kinase inhibitor-induced liver injury

作　　者：刘慧慧 魏静瑶 张丽珍[1] 冯进伟 刘瑞娟 田鑫[1] LIU Hui-hui;WEI Jing-yao;ZHANG Li-zhen;FENG Jin-wei;LIU Rui-juan;TIAN Xin(Dept of Pharmacy,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院药学部,河南郑州450052

出　　处：《中国药理学通报》2023年第9期1613-1617,共5页Chinese Pharmacological Bulletin

基　　金：国家自然科学基金资助项目(No 81903720)。

摘　　要：酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)为一类靶向抑癌基因相关受体酪氨酸激酶的小分子化合物,通过阻断下游的信号通路发挥抗癌作用。TKIs广泛用于癌症的治疗,对于部分肿瘤显示出较传统化疗药物更好的疗效。然而,TKIs引起的药物性肝损伤是其在临床应用中面临的难题之一。笔者通过查阅国内外相关文献,对TKIs的分类、临床应用及其引起肝损伤的机制等进行综述,以期为阐明TKIs肝损伤的机制和寻找有效的防治手段提供一定的参考。Tyrosine kinase inhibitors(TKIs)are a class of molecular targeted drugs that inhibit the activation of downstream signaling pathways by inhibiting oncogene-related receptor tyrosine kinases to exert anti-cancer effects.TKIs are superior to traditional chemotherapeutics in terms of selectivity,effectiveness and safety,and are widely used in the treatment of cancer.However,TKIs-induced liver injury is one of the difficult problems in its clinical application.In this article,relevant literatures from domestic and abroad are reviewed and the research progress in the classification,clinical application of TKIs and the mechanism of TKIs-induced liver injury are summarized.This review intends to provide a reference for further elucidating the mechanism of TKIs-induced liver injury,and seeking effective prevention and treatment methods.

关 键 词：酪氨酸激酶 酪氨酸激酶抑制剂 药物性肝损伤 靶向药物 机制 靶点 

分 类 号：R-05[医药卫生] R345.57R575R977.3